These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Monitoring fibrinolytic activity in the cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: a guide to the risk of rebleeding? Maurice-Williams RS; Gordon YB; Sykes A J Neurol Neurosurg Psychiatry; 1980 Feb; 43(2):175-81. PubMed ID: 7359154 [TBL] [Abstract][Full Text] [Related]
5. Monitoring of fibrin and fibrinogen degradation products (FDP) in the cerebrospinal fluid of patients with subarachnoid haemorrhage due to ruptured aneurysm. Report of 55 cases. Schisano G; Franco A; Nina P; Papa ML; Iannuzzi M; De Biase R; Caldora M J Neurosurg Sci; 1994 Jun; 38(2):77-86. PubMed ID: 7891197 [TBL] [Abstract][Full Text] [Related]
6. Fibrinolytic activity of cerebral tissue after experimental subarachnoid haemorrhage: inhibitory effect of tranexamic acid (AMCA). Fodstad H; Kok P; Algers G Acta Neurol Scand; 1981 Jul; 64(1):29-46. PubMed ID: 7198859 [TBL] [Abstract][Full Text] [Related]
7. Prediction of cerebral vasospasm value of fibrinogen degradation products (FDP) in the cerebro-spinal fluid (CSF) for prediction of vasospasm following subarachnoid haemorrhage due to a ruptured aneurysm. Guggiari M; Dagreou F; Rivierez M; Mottet P; Gallais S; Philippon J; Viars P Acta Neurochir (Wien); 1984; 73(1-2):25-33. PubMed ID: 6496196 [TBL] [Abstract][Full Text] [Related]
8. Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage. Vermeulen M; van Vliet HH; Lindsay KW; Hijdra A; van Gijn J J Neurosurg; 1985 Oct; 63(4):573-7. PubMed ID: 3897478 [TBL] [Abstract][Full Text] [Related]
9. Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity. Alvarez Garijo JA; Vilches JJ; Aznar JA J Neurosurg; 1980 Apr; 52(4):453-5. PubMed ID: 7373370 [TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic activity in CSF of patients with SAH in the acute phase measured by a rapid method (correlation with t-AMCA concentration in CSF. Nishimatsu T; Shibasaki T; Sasaki H; Nukui H Neurol Med Chir (Tokyo); 1981 Jan; 21(1):85-93. PubMed ID: 6168953 [No Abstract] [Full Text] [Related]
11. Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. Spallone A; Pastore FS; Rizzo A; Guidetti B Neurochirurgia (Stuttg); 1987 Nov; 30(6):172-6. PubMed ID: 2447515 [TBL] [Abstract][Full Text] [Related]
12. Fibrinolytic activity in blood and cerebrospinal fluid in subarachnoid hemorrhage from ruptured intracranial saccular aneurysm before and during EACA treatment. Filizzolo F; D'angelo V; Collice M; Ferrara M; Donati MB; Porta M Eur Neurol; 1978; 17(1):43-7. PubMed ID: 624294 [TBL] [Abstract][Full Text] [Related]
13. The fibrinolytic activity of cerebrospinal fluid after subarachnoid hemorrhage. Steinmetz H; Grote E Neurol Res; 1983; 5(4):59-65. PubMed ID: 6149487 [TBL] [Abstract][Full Text] [Related]
14. The role of antifibrinolytic therapy in the preoperative management of recently ruptured intracranial aneurysms. Guidetti B; Spallone A Surg Neurol; 1981 Apr; 15(4):239-48. PubMed ID: 6166061 [TBL] [Abstract][Full Text] [Related]
15. The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage. Schisano G Surg Neurol; 1978 Oct; 10(4):217-22. PubMed ID: 725719 [TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid. Tsementzis SA; Honan WP; Nightingale S; Hitchcock ER; Meyer CH Acta Neurochir (Wien); 1990; 103(3-4):116-21. PubMed ID: 2205078 [TBL] [Abstract][Full Text] [Related]
18. Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Fodstad H; Forssell A; Liliequist B; Schannong M Neurosurgery; 1981 Feb; 8(2):158-65. PubMed ID: 7010203 [TBL] [Abstract][Full Text] [Related]
19. Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. Chandra B Ann Neurol; 1978 Jun; 3(6):502-4. PubMed ID: 354483 [TBL] [Abstract][Full Text] [Related]
20. Monitoring of antifibrinolytic therapy following subarachnoid hemorrhage. The importance of CSF fibrin/fibrinogen degradation products. Sawaya R; Sonnino V; McLaurin RL; Perrotta G J Neurosurg; 1983 May; 58(5):699-707. PubMed ID: 6834119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]